Tempest Therapeutics Inc., a clinical-stage biotechnology company focused on developing targeted and immune-mediated cancer therapeutics, has announced a $4.6 million registered direct offering of common stock. This transaction involves the sale of 739,000 shares at $6.25 each to a single institutional investor. H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering. The company plans to use the net proceeds to support its strategic alternative process and for general corporate purposes. The offering is expected to close around June 12, 2025, pending customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.